Cost-effectiveness of extended-release niacin/laropiprant added to a stable simvastatin dose in secondary prevention patients not at cholesterol goal in Germany
Galin Michailov (),
Glenn Davies and
The European Journal of Health Economics, 2012, vol. 13, issue 3, pages 365-374
Keywords: Cost-effectiveness; Dyslipidaemia; Extended-release niacin; Hypercholesterolaemia; Laropiprant; Simvastatin; I10 (search for similar items in EconPapers)
References: Add references at CitEc
Citations Track citations by RSS feed
Downloads: (external link)
Access to full text is restricted to subscribers.
This item may be available elsewhere in EconPapers: Search for items with the same title.
Export reference: BibTeX
RIS (EndNote, ProCite, RefMan)
Persistent link: http://EconPapers.repec.org/RePEc:spr:eujhec:v:13:y:2012:i:3:p:365-374
Ordering information: This journal article can be ordered from
Access Statistics for this article
The European Journal of Health Economics is edited by J.-M.G.v.d. Schulenburg
More articles in The European Journal of Health Economics from Springer
Series data maintained by Guenther Eichhorn ().